Patients were considered for inclusion in the study if they were ≥70 years of age and were having elective TKA or THA. The study group and control group were matched as closely as possible for age, ...
Comprehensive Analysis of UGT1A Polymorphisms Predictive for Pharmacokinetics and Treatment Outcome in Patients With Non–Small-Cell Lung Cancer Treated With Irinotecan and Cisplatin The outcome in ...
The Hematology and Oncology Clinics of three US medical centres - Dartmouth-Hitchcock Medical Center (Lebanon, NH), Pacific Shores Medical Group (Long Beach, CA) and South Carolina Oncology Associates ...
Intravenous administration of epoetin alfa, a product that stimulates red blood cell production, to patients with heart attack who were undergoing percutaneous coronary intervention (PCI; procedures ...
Epoetin alfa administered to patients with STEMI within 4 hours of successful percutaneous coronary intervention was shown to increase the rate of adverse CV events while having no benefit on infarct ...
BRIDGEWATER, N.J., March 7 /PRNewswire/ -- Ortho Biotech Products, L.P. today modified prescribing information for PROCRIT(R) (Epoetin alfa), following guidance from the U.S. Food and Drug ...
Chemoendocrine Therapy for Premenopausal Women With Axillary Lymph Node–Positive, Steroid Hormone Receptor–Positive Breast Cancer: Results From INT 0101 (E5188) Eligible patients were randomly ...
The U.S. Food and Drug Administration today approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, ...
Between 1988 and 1998, antibody-associated pure red-cell aplasia was reported in three patients who had undergone treatment with recombinant human erythropoietin (epoetin). Between 1998 and 2000, 13 ...
Please provide your email address to receive an email when new articles are posted on . This week, the FDA released MedWatch alerts regarding the safety of three oncologic therapeutic agents. Chromic ...
FDA LOGO BLUE The approval of Retacrit was based on a review of evidence that included human pharmacokinetic/pharmacodynamic data and clinical immunogenicity data ...
Credit: Shutterstock Newly released safety data also show that roxadustat is associated with reduced cardiovascular risks compared with epoetin alfa. WASHINGTON—Roxadustat is superior to epoetin alfa ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results